Tyche Industries Ltd. | Balance Sheet

Fiscal year is April-March. All values INR Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
32,126.30
13,093.90
135,139.90
148,924.70
256,836.00
293,043
Total Accounts Receivable
167,486.70
178,639.20
162,099.50
99,677.50
97,019.00
104,255
Inventories
172,333.90
129,756.90
54,825.90
44,697.00
53,396.00
79,928
Other Current Assets
23,642.70
10,619.60
12,847.40
27,044.40
37,132.00
49,716
Total Current Assets
395,589.60
332,109.60
364,912.80
320,343.60
444,383.00
526,942
Net Property, Plant & Equipment
333,537.30
293,529.50
287,366.60
269,049.90
198,429.00
191,484
Total Investments and Advances
3,854.50
3,854.50
27.00
27.00
27.00
27
Long-Term Note Receivable
192.00
192.00
4,294.80
192.00
-
-
Other Assets
5,414.70
10,259.40
17,917.90
20,504.20
22,107.00
21,666
Total Assets
738,588.10
639,945.00
674,519.10
610,116.60
664,946.00
740,119
ST Debt & Current Portion LT Debt
103,381.20
86,873.90
108,269.00
-
-
Accounts Payable
113,371.40
70,436.20
74,105.30
69,379.50
54,349.00
Income Tax Payable
22,509.50
12,257.50
5,955.00
21,316.00
-
Other Current Liabilities
23,467.20
9,613.60
9,684.90
9,390.50
45,479.00
Total Current Liabilities
262,729.20
179,181.20
198,014.20
100,086.10
99,828.00
Long-Term Debt
10,787.70
-
-
-
-
Provision for Risks & Charges
3,523.70
5,428.00
8,280.80
11,633.20
13,528.00
Deferred Taxes
25,569.70
17,275.90
12,174.00
19,337.90
19,647.00
Other Liabilities
-
-
-
-
697.00
Total Liabilities
302,610.30
201,885.00
218,469.00
131,057.20
133,700.00
Common Equity (Total)
435,977.80
438,059.90
456,050.20
479,059.50
531,246.00
Total Shareholders' Equity
435,977.80
438,059.90
456,050.20
479,059.50
531,246.00
Total Equity
435,977.80
438,059.90
456,050.20
479,059.50
531,246.00
Liabilities & Shareholders' Equity
738,588.10
639,945.00
674,519.10
610,116.60
664,946.00

About Tyche Industries

View Profile
Address
H. No. C21/A, Road No. 9
Hyderabad TS 500096
India
Employees -
Website http://www.tycheindustries.com
Updated 07/08/2019
Tyche Industries Ltd. engages in the manufacture of active pharmaceutical ingredient and intermediates. It offers a range of products including Chiral intermediates and nutraceuticals for the treatment of various diseases including diarrhea, emetic, benign prostatic hypertrophy, retroviral, arthritis, inflammatory, microbacteria, and osteoporosis. The company was founded on July 23, 1998 and is headquartered in Hyderabad, India.